Lurbinectedin is a chemotherapy drug that has shown promising results in the treatment of various types of cancer. It is currently approved by the US FDA for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received chemotherapy [1].

According to a study published in the Journal of Clinical Oncology, Lurbinectedin has shown to be effective as a standalone treatment for patients with relapsed SCLC [2]. The study involved 105 patients who were given Lurbinectedin as a monotherapy. The results showed an overall response rate of 35%, with a median duration of response of 5.3 months. The study concluded that Lurbinectedin has significant activity as a single-agent treatment for relapsed SCLC.

Another study published in the Journal of Thoracic Oncology evaluated the efficacy and safety of Lurbinectedin in combination with doxorubicin in patients with advanced solid tumors. The study included 44 patients, and the results showed an overall response rate of 25%, with a median duration of response of 5.2 months [3]. The study concluded that the combination of Lurbinectedin and doxorubicin is a safe and effective treatment option for patients with advanced solid tumors.

In summary, Lurbinectedin has shown promising results as a standalone treatment for relapsed SCLC, with an overall response rate of 35% and a median duration of response of 5.3 months. Additionally, Lurbinectedin in combination with doxorubicin has shown to be a safe and effective treatment option for patients with advanced solid tumors. However, further research is needed to determine the efficacy of Lurbinectedin in other types of cancer and in combination with other treatments [2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.ispor.org/docs/default-source/intl2023/ispor23suposter123471-pdf?sfvrsn=9f8efc6c_0.